Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study

被引：0
|
作者：
Taylor, P. [1 ]
Genovese, M. [2 ]
Keystone, E. [3 ]
Schlichting, D. [4 ]
Beattie, S. [5 ]
Macias, W. [4 ]
Lundmark, J. [6 ]
机构：
[1] Univ Oxford, Kennedy Inst Rheumatol, Oxford OX1 2JD, England
[2] Stanford Univ, Immunol & Rheumatol Clin, Stanford, CA 94305 USA
[3] Mt Sinai Hosp, Rebecca MacDonald Ctr Arthrit & Autoimmune Dis, Toronto, ON M5G 1X5, Canada
[4] Eli Lilly & Co, Corp Ct, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Global Stat Sci Autoimmune Platform, Indianapolis, IN USA
[6] Eli Lilly Sweden AB, Biomed, Solna, Sweden
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2014年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP201
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [41] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Mueller, Ruediger B.
    Schulze-Koops, Hendrik
    Furst, Daniel E.
    Cohen, Stanley B.
    Kwok, Kenneth
    Wang, Lisy
    Killeen, Tim
    von Kempis, Johannes
    CLINICAL RHEUMATOLOGY, 2022, 41 (04) : 1045 - 1055
  • [42] Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study
    Genovese, Mark C.
    Kremer, Joel
    Zhong, Sheng
    Friedman, Alan
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [43] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK-1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN OPEN LABEL EXTENSION STUDY
    Genovese, M. C.
    Kremer, J.
    Zhong, S.
    Friedman, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 979 - 979
  • [44] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan J.
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Fleishaker, Dona
    Wang, Cunshan
    Kudlacz, Elizabeth
    Menon, Sujatha
    Fallon, Lara
    Hendrikx, Thijs
    Kanik, Keith S.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [45] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE SECOND INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, J. A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Hendrikx, T.
    Kanik, K. S.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S109 - S109
  • [46] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Fallon, L.
    Hendrikx, T.
    Kanik, K. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1010 - 1011
  • [47] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, J. A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Fallon, L.
    Hendrikx, T.
    Kanik, K. S.
    INTERNAL MEDICINE JOURNAL, 2018, 48 : 15 - 15
  • [48] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
    Brunner, Hermine I.
    Akikusa, Jonathan D.
    Al-Abadi, Eslam
    Bohnsack, John F.
    Boteanu, Alina Lucica
    Chedeville, Gaelle
    Cuttica, Ruben
    De La Pena, Wendy
    Jung, Lawrence
    Kasapcopur, Ozgur
    Kobusinska, Katarzyna
    Schulert, Grant S.
    Neiva, Claudia
    Rivas-Chacon, Rafael
    Rizo Rodriguez, Juan Cruz
    Vazquez-Del Mercado, Monica
    Wagner-Weiner, Linda
    Weiss, Jennifer E.
    Wouters, Carine
    Posner, Holly
    Wouters, Ann
    Chang, Cheng
    White, Claire
    Kanik, Keith
    Liu, Shixue
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (11) : 1561 - 1571
  • [49] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan J.
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Fleishaker, Dona
    Wang, Cunshan
    Kudlacz, Elizabeth
    Menon, Sujatha
    Hendrikx, Thijs
    Kanik, Keith S.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [50] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
    Brunner, Hermine I.
    Akikusa, Jonathan D.
    Al-Abadi, Eslam
    Bohnsack, John F.
    Boteanu, Alina Lucica
    Chedeville, Gaelle
    Cuttica, Ruben
    De La Pena, Wendy
    Jung, Lawrence
    Kasapcopur, Ozgur
    Kobusinska, Katarzyna
    Schulert, Grant S.
    Neiva, Claudia
    Rivas-Chacon, Rafael
    Rizo Rodriguez, Juan Cruz
    Vazquez-Del Mercado, Monica
    Wagner-Weiner, Linda
    Weiss, Jennifer E.
    Wouters, Carine
    Posner, Holly
    Wouters, Ann
    Chang, Cheng
    White, Claire
    Kanik, Keith
    Liu, Shixue
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (11) : 1561 - 1571
12345